Literature DB >> 11532106

An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease.

E M Wrone1, J L Zehnder, J M Hornberger, L M McCann, N S Coplon, S P Fortmann.   

Abstract

BACKGROUND: It is unclear whether total serum homocysteine (tHcy) and the C677T mutation of methylenetetrahydrofolate reductase (MTHFR) are associated with cardiovascular disease (CVD) in patients with end-stage renal disease (ESRD).
METHODS: A cross-sectional sample of 459 patients with ESRD on chronic dialysis was assessed to determine whether tHcy and the C677T mutation are associated with CVD prevalence in multiple logistic regression. As CVD mortality is high, we examined the relationship between homozygosity and duration of dialysis.
RESULTS: Mean tHcy was higher in patients without a history of CVD (35.2 micromol/L vs. 30.4 micromol/L, P = 0.02). In multivariate models, CVD was negatively associated with tHcy and positively associated with TT genotype, male gender, and body mass index. Mean tHcy levels were higher among those with the TT genotype compared with those with the CC genotype when adjusted for age, folate, creatinine, and albumin (37.9 micromol/L vs. 31.9 micromol/L, P = 0.005). Among whites, the prevalence of the TT genotype was higher in those having undergone less than one year of dialysis (P = 0.002).
CONCLUSIONS: The C677T genotype of MTHFR is associated with CVD in ESRD and may be a more meaningful marker than tHcy for abnormal homocysteine metabolism in ESRD. Prospective data from ongoing clinical trials are needed to improve our understanding of these findings. Screening for this polymorphism may help guide prevention measures.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11532106     DOI: 10.1046/j.1523-1755.2001.0600031106.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  8 in total

1.  Inadequacy of cardiovascular risk factor management in chronic kidney transplantation - evidence from the FAVORIT study.

Authors:  Myra A Carpenter; Matthew R Weir; Deborah B Adey; Andrew A House; Andrew G Bostom; John W Kusek
Journal:  Clin Transplant       Date:  2012-07-09       Impact factor: 2.863

Review 2.  Online tools for bioinformatics analyses in nutrition sciences.

Authors:  Sridhar A Malkaram; Yousef I Hassan; Janos Zempleni
Journal:  Adv Nutr       Date:  2012-09-01       Impact factor: 8.701

3.  Methylenetetrahydrofolate Reductase gene polymorphism in patients receiving hemodialysis.

Authors:  Emina Kiseljaković; Halima Resić; Lejla Kapur; Sabaheta Hasić; Radivoj Jadrić
Journal:  Bosn J Basic Med Sci       Date:  2010-04       Impact factor: 3.363

Review 4.  Genetic causation of neointimal hyperplasia in hemodialysis vascular access dysfunction.

Authors:  Timmy Lee; Davinder Wadehra
Journal:  Semin Dial       Date:  2011-09-15       Impact factor: 3.455

5.  Prevalence of methylenetetrahydrofolate gene (MTHFR) C677T polymorphism among chronic hemodialysis patients and its association with cardiovascular disease: a cross-sectional analysis.

Authors:  Salwa Ibrahim; Ola El Dessokiy
Journal:  Clin Exp Nephrol       Date:  2009-05-26       Impact factor: 2.801

6.  Contribution of GSTM1, GSTT1, and MTHFR polymorphisms to end-stage renal disease of unknown etiology in Mexicans.

Authors:  B E Gutiérrez-Amavizca; R Orozco-Castellanos; R Ortíz-Orozco; J Padilla-Gutiérrez; Y Valle; N Gutiérrez-Gutiérrez; G García-García; M Gallegos-Arreola; L E Figuera
Journal:  Indian J Nephrol       Date:  2013-11

7.  Potential Risk Factors Associated With Vascular Diseases in Patients Receiving Treatment for Hypertension.

Authors:  Hyunjung Kim; Joonhong Park; Hyojin Chae; Gun Dong Lee; Sang Yoon Lee; Jong Min Lee; Yong Seog Oh; Myungshin Kim; Yonggoo Kim
Journal:  Ann Lab Med       Date:  2016-05       Impact factor: 3.464

8.  Correlations of MTHFR 677C>T polymorphism with cardiovascular disease in patients with end-stage renal disease: a meta-analysis.

Authors:  Xian-Hui Gao; Guo-Yi Zhang; Ying Wang; Hui-Ying Zhang
Journal:  PLoS One       Date:  2014-07-22       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.